Effect of Metformin-sustained Release Therapy on Low-density Lipoprotein Size and Adiponectin in the South Indian Women with Polycystic Ovary Syndrome

Overview

Journal Indian J Endocrinol Metab

Specialty Endocrinology

Date 2017 Oct 10

PMID 28989873

Citations 2

Authors

D Rama Nagendra Kumar

Krishna G Seshadri

Monna Pandurangi

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study is to compare surrogate markers of cardiovascular disease (CVD) risk, such as adiponectin (APN) levels and low-density lipoprotein (LDL) size, before and after sustained release metformin (Met-SR) therapy in women with polycystic ovarian syndrome (PCOS).

Methods: Sixty women with PCOS and sixty age-matched controls in the age group 18-45 years were recruited after obtaining informed consent. Women with PCOS were initiated on Met-SR 1 g orally, which was increased to 1.5 g after 2 weeks and continued up to 24 weeks. Demographic data along with family history of type 2 diabetes mellitus, PCOS, and CVD were collected. Lipid profile plasma APN levels and LDL size were measured before and after therapy in the PCOS group. Data analysis was performed using the GraphPad Prism-5 software.

Results: Women with PCOS had greater dyslipidemia, lower APN level and LDL size, and increased lipid accumulating product index as compared to controls. After 6 months of Met-SR therapy, women with PCOS demonstrated significant increase in plasma APN levels and LDL size and significant decrease in weight, waist-hip ratio (WHR), waist circumference (WC), and blood pressure (BP). A significant decrease was observed in body mass index (BMI) in the overweight and obese PCOS subgroups.

Conclusion: Met-SR increases LDL size, APN concentration and decreases weight, WC, WHR, and BP in patients with PCOS. Met-SR may have salutary effects on LDL particle size through effects on APN levels in women with PCOS.

Citing Articles

Comparative Analysis of Psychosocial Outcomes and Quality of Life Among Nulligravida, Primigravida, and Multigravida Women Diagnosed With Polycystic Ovary Syndrome (PCOS).

Rehman F, Muslim Khan M, Lnu A, Lnu N, Lnu R, Zeb S Cureus. 2025; 17(3):e79895.

PMID: 40034417 PMC: 11873508. DOI: 10.7759/cureus.79895.

Evaluation of Lipids and Lipid-Related Transcripts in Human and Ovine Theca Cells and an Mouse Model Exposed to the Obesogen Chemical Tributyltin.

Pascuali N, Pu Y, Waye A, Pearl S, Martin D, Sutton A Environ Health Perspect. 2024; 132(4):47009.

PMID: 38630605 PMC: 11023052. DOI: 10.1289/EHP13955.

LKB1 suppresses androgen synthesis in a mouse model of hyperandrogenism via IGF-1 signaling.

Xu Y, Gao Y, Huang Z, Zheng Y, Teng W, Zheng D FEBS Open Bio. 2019; 9(10):1817-1825.

PMID: 31433577 PMC: 6768104. DOI: 10.1002/2211-5463.12723.

References

Perez A, Jacks R, Arora V, Spanheimer R . Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2010; 12(12):973-82. PMC: 8672983. DOI: 10.1111/j.1751-7176.2010.00389.x. View

Aziz N, Kallur S, Nirmalan P . Implications of the revised consensus body mass indices for asian indians on clinical obstetric practice. J Clin Diagn Res. 2014; 8(5):OC01-3. PMC: 4080037. DOI: 10.7860/JCDR/2014/8062.4212. View

Tsao T, Lodish H, Fruebis J . ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002; 440(2-3):213-21. DOI: 10.1016/s0014-2999(02)01430-9. View

Sivalingam V, Myers J, Nicholas S, Balen A, Crosbie E . Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update. 2014; 20(6):853-68. DOI: 10.1093/humupd/dmu037. View

Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu P . Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy. Indian J Clin Biochem. 2011; 25(4):367-70. PMC: 2994574. DOI: 10.1007/s12291-010-0090-2. View

Dejager S, Pichard C, Giral P, Bruckert E, Federspield M, Beucler I . Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001; 54(4):455-62. DOI: 10.1046/j.1365-2265.2001.01245.x. View

Ani M, Moshtaghie A, Ahmadvand H . Comparative effects of copper, iron, vanadium and titanium on low density lipoprotein oxidation in vitro. Iran Biomed J. 2007; 11(2):113-118. View

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Kulshreshtha B, Singh S, Arora A . Family background of Diabetes Mellitus, obesity and hypertension affects the phenotype and first symptom of patients with PCOS. Gynecol Endocrinol. 2013; 29(12):1040-4. DOI: 10.3109/09513590.2013.829446. View

10.

Milewicz A . Metformin for polycystic ovary syndrome. Endokrynol Pol. 2013; 64(5):409-14. DOI: 10.5603/EP.2013.0025. View

11.

Pavicic Baldani D, Skrgatic L, Ougouag R . Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women. Int J Endocrinol. 2015; 2015:786362. PMC: 4466395. DOI: 10.1155/2015/786362. View

12.

Hamed H . Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. J Obstet Gynaecol Res. 2013; 39(12):1596-603. DOI: 10.1111/jog.12101. View

13.

Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J . Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001; 161(22):2685-92. DOI: 10.1001/archinte.161.22.2685. View

14.

Dudman N, Blades B, Wilcken D, Aitken J . Radial immunodiffusion assay of apolipoprotein B in blood dried on filter paper--a potential screening method for familial type II hypercholesterolaemia. Clin Chim Acta. 1985; 149(2-3):117-27. DOI: 10.1016/0009-8981(85)90325-0. View

15.

Huypens P, Quartier E, Pipeleers D, Van de Casteele M . Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol. 2005; 518(2-3):90-5. DOI: 10.1016/j.ejphar.2005.06.016. View

16.

Peigne M, Dewailly D . Long term complications of polycystic ovary syndrome (PCOS). Ann Endocrinol (Paris). 2014; 75(4):194-9. DOI: 10.1016/j.ando.2014.07.111. View

17.

Ai M, Otokozawa S, Asztalos B, White C, Cupples L, Nakajima K . Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis. 2011; 217(2):543-8. PMC: 3662557. DOI: 10.1016/j.atherosclerosis.2011.05.035. View

18.

Agarwal N, Rice S, Bolusani H, Luzio S, Dunseath G, Ludgate M . Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2009; 95(2):722-30. DOI: 10.1210/jc.2009-1985. View

19.

Schmid P, Resch M, Schach C, Birner C, Riegger G, Luchner A . Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats. Cardiovasc Diabetol. 2013; 12:46. PMC: 3606629. DOI: 10.1186/1475-2840-12-46. View

20.

Trolle B, Lauszus F, Frystyk J, Flyvbjerg A . Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril. 2010; 94(6):2234-8. DOI: 10.1016/j.fertnstert.2010.01.057. View